Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.45 |
| ▸ | PI4KA | P42356 | 2/20 | 0.45 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.45 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.45 |
| ▸ | SLC28A1 | O00337 | 2/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.45 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.45 |
| ▸ | GAPDH | P04406 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | STAT6 | P42226 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31644935 | 1.00 | EGFR (0.47) | EGFRADORA3ADORA2API4KAPI4K2B | |
| SCHEMBL30041710 | 0.96 | DOT1L (0.45) | EGFRADORA3ADORA2API4KAPI4K2B | |
| SCHEMBL9501856 | 0.95 | EGFR (0.43) | EGFRADORA3ADORA2API4KAPI4K2B | |
| SCHEMBL2205117 | 0.92 | EGFR (0.44) | EGFRADORA3ADORA2API4KAPI4K2B | |
| SCHEMBL4916912 | 0.90 | ADORA3 (0.48) | EGFRADORA3ADORA2API4KAPI4K2B | |
| SCHEMBL7156326 | 0.89 | EGFR (0.42) | EGFRADORA3ADORA2API4KAPI4K2B | |
| SCHEMBL4451633 | 0.89 | ADORA3 (0.43) | EGFRADORA3ADORA2API4KAPI4K2B | |
| SCHEMBL30406718 | 0.89 | EGFR (0.42) | EGFRADORA3ADORA2API4KAPI4K2B | |
| SCHEMBL337874 | 0.89 | ADORA3 (0.45) | ADORA3ADORA2API4KAPI4K2BPI4K2A | |
| Phosphoric Acid SCHEMBL16070005 | 0.89 | ADORA3 (0.42) | EGFRADORA3ADORA2API4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 307 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117886868-A | Preparation method of 5' -DMT nucleoside compound | 天津奥瑞芙生物医药有限公司 | 2024-04-16 | — | — | CN | claimed |
| WO-2006038865-A1 | NUCLEOTIDE DERIVATIVES FOR THE TREATMENT OF TYPE 2 DIABETES AND OTHER DISORDERS | BETAGENON AB (SE) | 2006-04-13 | — | — | WO | claimed |
| US-12576099-B2 | Ribose-modified cap analog and use thereof | BEIJING YOUCARE KECHUANG PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2026-03-17 | — | — | US | disclosed |
| US-20260071217-A1 | ANTISENSE OLIGOMER COMPOUNDS | SAREPTA THERAPEUTICS, INC. (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4650358-A2 | RIBOSE-MODIFIED CAP ANALOG AND USE THEREOF | Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. (CN) | 2025-11-19 | — | — | EP | disclosed |
| US-12474327-B2 | Metabolic profiling for the diagnosis of a subset of idiopathic autism spectrum disorder patients, ADS Phenotype 1 | STALICLA SA (CH) | 2025-11-18 | — | — | US | disclosed |
| US-20250332189-A1 | RIBOSE-MODIFIED CAP ANALOG AND USE THEREOF | BEIJING YOUCARE KECHUANG PHARMACEUTICAL TECH CO LTD (CN) | 2025-10-30 | — | — | US | disclosed |
| US-20250241940-A1 | MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2025-07-31 | — | — | US | disclosed |
| US-20250171779-A1 | ANTISENSE OLIGOMERS AND METHODS OF USING THE SAME FOR TREATING DISEASES ASSOCIATED WITH THE ACID ALPHA-GLUCOSIDASE GENE | SAREPTA THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-20250171783-A1 | ANTISENSE-INDUCED EXON2 INCLUSION IN ACID ALPHA-GLUCOSIDASE | SAREPTA THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| EP-4493694-A1 | MODIFIED GAPMER OLIGOMERS AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| WO-1993003052-A1 | MULTIDOMAIN DNA LIGANDS FOR PROTEIN AND NUCLEIC ACID AFFINITY CHROMATOGRAPHY AND PROCESSING OF SOLID-PHASE DNA | ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 1993-02-18 | — | — | WO | disclosed |
| EP-0420872-A4 | THERAPEUTIC USES OF 2',5'-OLIGOADENYLATE DERIVATIVES | — | 1992-10-21 | — | — | EP | disclosed |
| WO-1991010671-A1 | COMPOSITIONS AND METHODS FOR DETECTING AND MODULATING RNA ACTIVITY AND GENE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 1991-07-25 | — | — | WO | disclosed |
| EP-0420872-A1 | THERAPEUTIC USES OF 2',5'-OLIGOADENYLATE DERIVATIVES. | UNIV TEMPLE (US) | 1991-04-10 | — | — | EP | disclosed |
| CN-1040321-A | 2 ', 5 '-therapeutic use of oligomerization adenylic acid derivant | UNIV TEMPLE (US) | 1990-03-14 | — | — | CN | disclosed |
| EP-0270651-A4 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES. | CALIFORNIA INST OF TECHN (US) | 1989-03-29 | — | — | EP | disclosed |
| EP-0270651-A1 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES. | CALIFORNIA INST OF TECHN (US) | 1988-06-15 | — | — | EP | disclosed |
| WO-1988000201-A1 | NOVEL DEOXYRIBONUCLEOSIDE PHOSPHORAMIDITES AND THEIR USE FOR THE PREPARATION OF OLIGONUCLEOTIDES | CALIFORNIA INSTITUTE OF TECHNOLOGY, INC. (US) | 1988-01-14 | — | — | WO | disclosed |
| EP-0121112-B1 | 2'-DEOXY-3-PHOSPHONYLMETHYL NUCLEOSIDES AND METHOD FOR THEIR PREPARATION | Gesellschaft für Biotechnologische Forschung mbH (GBF) (DE) | 1987-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576099-B2 | Ribose-modified cap analog and use thereof | RNMT, RNGTT, NSUN2 | EGFR 4803/4885ADORA3 1776/4885ADORA2A 1039/4885 |
| US-20260071217-A1 | ANTISENSE OLIGOMER COMPOUNDS | DCLRE1B, OGG1, DCTD | EGFR 1618/4885ADORA3 279/4885ADORA2A 362/4885 |
| US-20250332189-A1 | RIBOSE-MODIFIED CAP ANALOG AND USE THEREOF | RNMT, RNGTT, CPSF1 | EGFR 4565/4885ADORA3 941/4885ADORA2A 557/4885 |
| US-20250171779-A1 | ANTISENSE OLIGOMERS AND METHODS OF USING THE SAME FOR TREATING DISEASES ASSOCIATED WITH THE ACID ALPHA-GLUCOSIDASE GENE | GAA, GBA3, GBA1 | EGFR 4749/4885ADORA3 2466/4885ADORA2A 3135/4885 |
| US-20250241940-A1 | MODIFIED ANTISENSE OLIGOMERS FOR EXON INCLUSION IN SPINAL MUSCULAR ATROPHY | SMN1; SMN2, UPF1, RBM17 | EGFR 4535/4885ADORA3 3348/4885ADORA2A 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.